NasdaqCM - Delayed Quote USD

Pulse Biosciences, Inc. (PLSE)

7.19

+0.50

(+7.47%)

At close: April 26 at 4:00 PM EDT

7.34

+0.15

(+2.09%)

After hours: April 26 at 5:19 PM EDT

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for PLSE

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript

Q4 2023 Pulse Biosciences Inc Earnings Call

Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth

Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Insiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchases

Insiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchases

NYXH Nyxoah S.A.

10.62

-1.30%

BLFS BioLife Solutions, Inc.

17.53

+3.97%

BIG1.DE Bio-Gate AG

0.9900

-1.00%

BIOT.ST Biotage AB (publ)

165.50

+1.47%

NXGL NEXGEL, Inc.

2.2100

-5.15%

KRMD KORU Medical Systems, Inc.

2.1900

0.00%

ALIF-B.ST AddLife AB (publ)

98.65

+2.02%

BONEX.ST Bonesupport Holding AB (publ)

232.00

-2.36%

ALC.SW Alcon Inc.

72.00

+0.61%

CTEC.L ConvaTec Group PLC

257.80

-6.46%